- Home
- GRNT vs TBPH Comparison
GRNT vs TBPH Comparison
Compare GRNT & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRNT
- TBPH
- Stock Information
- Founded
- GRNT 2013
- TBPH 2013
- Country
- GRNT United States
- TBPH United States
- Employees
- GRNT N/A
- TBPH N/A
- Industry
- GRNT Blank Checks
- TBPH Biotechnology: Pharmaceutical Preparations
- Sector
- GRNT Finance
- TBPH Health Care
- Exchange
- GRNT Nasdaq
- TBPH Nasdaq
- Market Cap
- GRNT 675.9M
- TBPH 699.0M
- IPO Year
- GRNT N/A
- TBPH N/A
- Fundamental
- Price
- GRNT $5.19
- TBPH $18.42
- Analyst Decision
- GRNT Buy
- TBPH Strong Buy
- Analyst Count
- GRNT 1
- TBPH 4
- Target Price
- GRNT $8.00
- TBPH $24.25
- AVG Volume (30 Days)
- GRNT 452.9K
- TBPH 451.2K
- Earning Date
- GRNT 11-06-2025
- TBPH 11-10-2025
- Dividend Yield
- GRNT 8.49%
- TBPH N/A
- EPS Growth
- GRNT N/A
- TBPH N/A
- EPS
- GRNT 0.29
- TBPH 0.58
- Revenue
- GRNT $427,828,000.00
- TBPH $80,327,000.00
- Revenue This Year
- GRNT $35.82
- TBPH $79.82
- Revenue Next Year
- GRNT $10.41
- TBPH N/A
- P/E Ratio
- GRNT $18.03
- TBPH $31.09
- Revenue Growth
- GRNT 19.33
- TBPH 27.12
- 52 Week Low
- GRNT $4.52
- TBPH $7.90
- 52 Week High
- GRNT $7.00
- TBPH $18.96
- Technical
- Relative Strength Index (RSI)
- GRNT 46.61
- TBPH 72.62
- Support Level
- GRNT $5.07
- TBPH $16.82
- Resistance Level
- GRNT $5.29
- TBPH $18.21
- Average True Range (ATR)
- GRNT 0.16
- TBPH 0.89
- MACD
- GRNT -0.00
- TBPH 0.34
- Stochastic Oscillator
- GRNT 53.28
- TBPH 88.66
About GRNT Granite Ridge Resources Inc.
Granite Ridge Resources Inc is a scaled, non-operated oil and gas exploration and production company. It invests in a diversified portfolio of production and top-tier acreage across the Permian and other prolific U.S. basins in partnership with operators. It generates maximum revenue from Oil.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).